SOCRA - Society of Clinical Research Associates Audits, Monitoring, and Inspections Questions and Answers

Question 1

Which of the following best describes the primary purpose of a sponsor-initiated quality assurance audit of a clinical trial site?

Accepted Answer

To provide a systematic and independent examination of trial-related activities and documents to determine compliance with the protocol, GCP, and regulatory requirements.

Answer

To perform source data verification for 100% of all data points entered into the CRF.

Answer

To train the site staff on the protocol and investigational product accountability.

Answer

To report serious adverse events directly to the regulatory authorities on behalf of the site.

Question 2

A clinical research site receives notification from the FDA of a forthcoming 'for-cause' inspection. This type of inspection is most likely triggered by what?

Accepted Answer

A specific concern, such as a complaint, unusual pattern of adverse events, or evidence of significant non-compliance.

Answer

A standard review process for a New Drug Application (NDA) submission.

Answer

A randomly selected site as part of the FDA's routine bioresearch monitoring program.

Answer

The site enrolling the highest number of participants in a multi-center trial.

Question 3

During a routine on-site monitoring visit, a Clinical Research Associate (CRA) is responsible for all of the following activities EXCEPT:

Accepted Answer

Issuing an official FDA Form 483 for observed regulatory non-compliance.

Answer

Verifying that informed consent was obtained prior to any study-specific procedures.

Answer

Comparing data in the source documents with the entries in the Case Report Forms (CRFs).

Answer

Checking the storage conditions and accountability of the investigational product.

Question 4

An FDA inspector concludes an inspection of a clinical site and issues a Form FDA 483 with three observations. What is the most critical next step for the Principal Investigator?

Accepted Answer

Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan.

Answer

Wait for the sponsor to handle all communication with the FDA.

Answer

Immediately stop all trial activities until the observations are resolved.

Answer

Appeal the findings to the Institutional Review Board (IRB).

Question 5

A sponsor is implementing a risk-based monitoring approach for a large, multi-center trial. Which of the following best characterizes this strategy?

Accepted Answer

Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk.

Answer

Eliminating all on-site monitoring visits in favor of remote data review only.

Answer

Requiring 100% source data verification for every participant at every site, regardless of site performance.

Answer

Assigning the responsibility of site monitoring entirely to the Institutional Review Board (IRB).

Question 6

During an FDA inspection, the inspector requests access to the electronic medical records (EMR) of enrolled subjects, which are the designated source documents. The site staff should:

Accepted Answer

Provide direct, supervised access to the relevant sections of the EMR for the subjects who provided consent.

Answer

Refuse access, stating that EMRs are confidential hospital property and not subject to FDA review.

Answer

Print out every page of the subjects' entire medical history for the inspector to review.

Answer

Tell the inspector to request the records directly from the hospital's legal department.